Myovant rejects Sumitovant and Sumitomo’s $2.5bn acquisition offer
Pharmaceutical Technology
OCTOBER 3, 2022
Myovant Sciences has rejected an acquisition offer worth $2.5bn from Sumitovant Biopharma and its wholly-owned subsidiary Sumitomo Pharma, citing it 'significantly undervalues' the company. The board of directors of Myovant constituted a special committee of independent directors including its audit committee members to assess the proposal.
Let's personalize your content